期刊文献+

CYP450基因多态性对抗肿瘤药物影响的研究进展 被引量:2

Research Progress of the Effect of the Polymorphisms of CYP450 Genes on Anti-tumor Drugs
下载PDF
导出
摘要 药物代谢酶的差异是药物个体疗效和副作用差异的决定因素之一。作为I相药物代谢酶,细胞色素P450酶及其编码基因在不同种群、不同个体之间均存在着差异和突变,这种基因的多态性导致了肿瘤患者对抗肿瘤药物的敏感性及预后的不同,本文就CYP家族的基因多态性对抗肿瘤药物的药动学、药效学及不良反应的影响进行综述,以期为抗肿瘤药物的个体化给药提供参考。 The difference in drug metabolizing enzymes was one of the determinants of drug efficacy and side effects of individual differences. As a phase I drug metabolizing enzyme, Cytochrome P450, and their coding genes had their differences and mutation in different populations and different individuals. Polymorphism in this gene led to its different sensitivity to anti tumor drugs and prognosis of cancer patients. In this review, the influence of gene polymorphism of CYP family on pharmacokinetic, pharmacodynamic and adverse reaction in anti tumor drugs were summarized in order to provide a reference for the individual administration of anti tumor drugs.
出处 《药物流行病学杂志》 CAS 2014年第4期252-257,共6页 Chinese Journal of Pharmacoepidemiology
关键词 CYP450 基因多态性 抗肿瘤药物 CYP450 Gene polymorphism Anti-tumor drug
  • 相关文献

参考文献48

  • 1王娜,韩俊领,秘营昌,肖志坚,冯四洲,周毓玲,王建祥,韩明哲.药物代谢酶基因多态性与初治急性髓系白血病初次诱导治疗结果的相关性研究[J].中国实验血液学杂志,2011,19(2):327-331. 被引量:1
  • 2郑波,黄海燕,刘建军,王晓梅.CYP1A1、CYP2E1基因多态性与癌症易感性的研究进展[J].癌变.畸变.突变,2010,22(3):243-245. 被引量:8
  • 3肖鹏,周宏灏.细胞色素氧化酶CYP1A2的研究进展[J].中南大学学报(医学版),2008,33(5):456-460. 被引量:36
  • 4张明,柳晓泉.肿瘤组织中的CYP1B1及其抑制剂的抗肿瘤活性[J].药学进展,2009,33(4):157-162. 被引量:2
  • 5Dong N,Yu J, Wang C,et al. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer trea- ted with docetaxel plus capecitabine [ J ]. J Cancer Res Clin Onco1,2012,138 (7) : 1197-1203.
  • 6Van Erp NP, Eechoute K,van der Veldt AA,et al. Pharmaco- genetic pathway analysis for determination of sunitinib-in-duced toxicity[J]. J Clin 0ncot,2009,27(26) :4406-4412.
  • 7Nie Q,Yang XN,An SJ,et al. CYP1A1 *2A polymorphism as a predictor of clinical outcome in advanced lung cancer pa- tients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism [ J ]. Eur J Cancer, 2011,47 (13) : 1962-1970.
  • 8Laroche-Clary A, Le Morvan V, Yamori T, et al. Cytochrome P450 1 B1 gene polymorphisms as predictors of anticancer drug activity: sudies with in vitro models [ J ]. Mol Cancer Ther', 2010,9(12) :3315-3321.
  • 9Pastira I, Giovannetti E ,Chioni A ,et al. Cytochrome 450 1 B1 (CYP1B1) potymorphisms associated with response to do- cetaxel in Castration-Resistant Prostate Cancer (CRPC) pa- tients [ J ]. BMC Cancer,2010,10:511.
  • 10Rizza R,-Spaggiari F,hadelli M,et al. Association of CYP1B1 with hypersensitivity iodueed by taxane therapy in breast eancer patients [ J ]. Breast Cancer Res Treat, 2010,124 ( 2 ) : 593-598.

二级参考文献201

共引文献71

同被引文献25

  • 1杨宝峰.药理学[M].第7版.北京:人民卫生出版社,2008:135-136.
  • 2Ahmed EM, EL-Maraghy SA, Teleb ZA,et al. Pretreatment with tur- meric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2EI and CYP3A1/2 in isolated rat hepatic microsomes [ J ]. Chemico-Biological Interactions ,2014,220:25-32.
  • 3Graen H, Khan MS, Jakobsen-Falk I,et al. Impact of CYP3A5 * 3 and CYF2C8-HapC on paclitaxel/carboplatin-induced myelosuppres- sion in patients with ovarian cancer[J]. J Pharm Sci. ,2011,100 (10) :4205-4209.
  • 4Apelldniz-Ruiz M, Lee MY, Sdnchez-Barroso L,et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy[ J ]. Clin Cancer Res, 2015 , 21 ( 2 ) : 322- 328.
  • 5Joerger M, Kraft S, Huitema AD,et al. Evaluation of a pharmacolo- gy-driven dosing algorithm of 3-weeldy paclitaxel using therapeutic drug monitoring simulation stud- y[J]. Clin Pharmacokinet ,2012 ,51 (9) :607-617.
  • 6Okamoto I, Yamamoto N, Kubota K, et ad. Safety and pharmacoki- netic study of nab-paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer [J ]. Invest New Drugs ,2012,30(3 ) : 1132-1137.
  • 7Vasile E, Tibaldi C, Leon GL, et al. Cytochrome P450 1B1 ( CYPIB1 ) polymorphisms are associated with clinical outcome of do- cetaxel in non-small cell lung cancer (NSCLC) patients[ J ]. J Cancer Res Clin 0ncol,2015,141(7) :1189-1194.
  • 8Deng S, Wang C, Zhang W,et al. Effect of triacontanol on the phar- macokinetics of docetaxel in rats associated with induction of cyto- chrome P4503A1/2 [ J]. Xenobiotica ,2014,44(7 ) :583-590.
  • 9Mooiman KD, Maas-Bakker RF, Hendrikx JJ, et al. The effect of complementary and alternative medicines on CYP3A4-mediated me- tabolism of three different substrates: 7-benzyloxy-4-trilluoromethyl- coumarin, midazolam and docetaxel[ J ]. J Pharm Pharmaco1,2014, 66(6) :865-874.
  • 10钟皎,赵文艳,王丽萍.高效液相色谱法测定非小细胞肺癌患者血浆中紫杉醇浓度[J].中国医院药学杂志,2008,28(7):538-540. 被引量:11

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部